Prevention of prostate cancer

outcomes of clinical trials and future opportunities

Ian Thompson, Alan Kristal, Elizabeth A. Platz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Prostate cancer is an excellent target for prevention, to reduce both mortality and the burden of overdetection of potential inconsequential disease whose diagnosis increases cost, morbidity, and anxiety. The Prostate Cancer Prevention Trial has demonstrated that finasteride significantly reduces the risk of prostate cancer but only low-grade disease; overall survival is unaffected. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) clinical trial, selenium had no effect on prostate cancer risk, but alpha tocopherol significantly increased the risk by 17%. The most promising future approaches to prostate cancer prevention will likely focus on nutrition, especially weight control, and through modulation of inflammation.

Original languageEnglish (US)
Pages (from-to)e76-e80
JournalAmerican Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Clinical Trials
Selenium
Finasteride
alpha-Tocopherol
Vitamin E
Anxiety
Inflammation
Morbidity
Weights and Measures
Costs and Cost Analysis
Mortality
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{f92eb0dd97194ba49bf900ff0f632699,
title = "Prevention of prostate cancer: outcomes of clinical trials and future opportunities",
abstract = "Prostate cancer is an excellent target for prevention, to reduce both mortality and the burden of overdetection of potential inconsequential disease whose diagnosis increases cost, morbidity, and anxiety. The Prostate Cancer Prevention Trial has demonstrated that finasteride significantly reduces the risk of prostate cancer but only low-grade disease; overall survival is unaffected. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) clinical trial, selenium had no effect on prostate cancer risk, but alpha tocopherol significantly increased the risk by 17{\%}. The most promising future approaches to prostate cancer prevention will likely focus on nutrition, especially weight control, and through modulation of inflammation.",
author = "Ian Thompson and Alan Kristal and Platz, {Elizabeth A.}",
year = "2014",
doi = "10.14694/EdBook_AM.2014.34.e76",
language = "English (US)",
pages = "e76--e80",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Prevention of prostate cancer

T2 - outcomes of clinical trials and future opportunities

AU - Thompson, Ian

AU - Kristal, Alan

AU - Platz, Elizabeth A.

PY - 2014

Y1 - 2014

N2 - Prostate cancer is an excellent target for prevention, to reduce both mortality and the burden of overdetection of potential inconsequential disease whose diagnosis increases cost, morbidity, and anxiety. The Prostate Cancer Prevention Trial has demonstrated that finasteride significantly reduces the risk of prostate cancer but only low-grade disease; overall survival is unaffected. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) clinical trial, selenium had no effect on prostate cancer risk, but alpha tocopherol significantly increased the risk by 17%. The most promising future approaches to prostate cancer prevention will likely focus on nutrition, especially weight control, and through modulation of inflammation.

AB - Prostate cancer is an excellent target for prevention, to reduce both mortality and the burden of overdetection of potential inconsequential disease whose diagnosis increases cost, morbidity, and anxiety. The Prostate Cancer Prevention Trial has demonstrated that finasteride significantly reduces the risk of prostate cancer but only low-grade disease; overall survival is unaffected. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) clinical trial, selenium had no effect on prostate cancer risk, but alpha tocopherol significantly increased the risk by 17%. The most promising future approaches to prostate cancer prevention will likely focus on nutrition, especially weight control, and through modulation of inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84964698761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964698761&partnerID=8YFLogxK

U2 - 10.14694/EdBook_AM.2014.34.e76

DO - 10.14694/EdBook_AM.2014.34.e76

M3 - Article

SP - e76-e80

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

ER -